Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery

SummaryThe worldwide market for therapies for CNS disorders is worth more than $50 billion and is set to grow substantially in the years ahead. This is because: 1) the incidence of many CNS disorders (e.g., Alzheimer’s disease, stroke, and Parkinson’s disease) increase exponentially after age 65 and 2) the number of people in the world over 65 is about to increase sharply because of a marked rise in fertility after World War II. However, CNS research and development are associated with significant challenges: it takes longer to get a CNS drug to market (12–16 years) compared with a non-CNS drug (10–12 years) and there is a higher attrition rate for CNS drug candidates than for non-CNS drug candidates. This is attributable to a variety of factors, including the complexity of the brain, the liability of CNS drugs to cause CNS side effects, and the requirement of CNS drugs to cross the blood-brain barrier (BBB). This review focuses on BBB penetration, along with pharmacokinetics and drug metabolism, in the process of the discovery and development of safe and effective medicines for CNS disorders.

[1]  I. Wilhelm,et al.  In vitro models of the blood-brain barrier. , 2011, Acta neurobiologiae experimentalis.

[2]  J. Kornhuber,et al.  Region specific distribution of levomepromazine in the human brain , 2006, Journal of Neural Transmission.

[3]  M. Pathy,et al.  Principles and practice of geriatric medicine , 2005 .

[4]  D. E. Clark,et al.  In Silico Predictions of Blood-Brain Barrier Penetration: Considerations to “Keep in Mind” , 2005, Journal of Pharmacology and Experimental Therapeutics.

[5]  Raimund Mannhold,et al.  Second-Generation KATP Channel Openers , 2005 .

[6]  Huadong Tang,et al.  A NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALING , 2005, Drug Metabolism and Disposition.

[7]  R. Mckernan,et al.  In vivo labelling of α5 subunit-containing GABAA receptors using the selective radioligand [3H]L-655,708 , 2005, Neuropharmacology.

[8]  W. Sneader.  Drug Discovery: A History , 2005 .

[9]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[10]  W. Liang,et al.  A simple predictive model for blood-brain barrier penetration. , 2005, Die Pharmazie.

[11]  A. Green,et al.  Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. , 2005, Current drug targets. CNS and neurological disorders.

[12]  J. Ghersi-Egea,et al.  Factors affecting delivery of antiviral drugs to the brain , 2005, Reviews in medical virology.

[13]  T. Molski,et al.  Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130 , 2005, Pharmacology Biochemistry and Behavior.

[14]  Christel A. S. Bergström,et al.  In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption. , 2005, Basic & clinical pharmacology & toxicology.

[15]  S. Nyberg,et al.  Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. , 2005, The international journal of neuropsychopharmacology.

[16]  C. O'brien.  Benzodiazepine use, abuse, and dependence. , 2005, The Journal of clinical psychiatry.

[17]  Masami Niwa,et al.  Permeability Studies on In Vitro Blood–Brain Barrier Models: Physiology, Pathology, and Pharmacology , 2005, Cellular and Molecular Neurobiology.

[18]  N. Abbott.  Dynamics of CNS Barriers: Evolution, Differentiation, and Modulation , 2005, Cellular and Molecular Neurobiology.

[19]  Raimund Mannhold,et al.  The impact of lipophilicity in drug research: a case report on beta-blockers. , 2005, Mini reviews in medicinal chemistry.

[20]  I. Hidalgo,et al.  Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. , 2005, International journal of pharmaceutics.

[21]  C. Blanco,et al.  Sertraline treatment of pathological gambling: a pilot study. , 2005, The Journal of clinical psychiatry.

[22]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[23]  P. Worboys,et al.  Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L‐838417 , 2005, Biopharmaceutics & drug disposition.

[24]  P. Patsalos,et al.  The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus) , 2004, Seizure.

[25]  Vesna Sossi,et al.  Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. , 2004, Brain : a journal of neurology.

[26]  Danny D Shen,et al.  Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. , 2004, Advanced drug delivery reviews.

[27]  Yuming Huang,et al.  Binding study of drug with bovine serum album using a combined technique of microdialysis with flow-injection chemiluminescent detection. , 2004, Journal of pharmaceutical and biomedical analysis.

[28]  A. Palmer,et al.  The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines. , 2004, IDrugs : the investigational drugs journal.

[29]  Manfred Kansy,et al.  Predicting plasma protein binding of drugs--revisited. , 2004, Current opinion in drug discovery & development.

[30]  J. Brotchie,et al.  Drugs in development for Parkinson's disease. , 2004, Current opinion in investigational drugs.

[31]  D. Kassel,et al.  Applications of high-throughput ADME in drug discovery. , 2004, Current opinion in chemical biology.

[32]  M. Nedergaard,et al.  The blood–brain barrier: an overview Structure, regulation, and clinical implications , 2004, Neurobiology of Disease.

[33]  Gerhard F. Ecker,et al.  In silico prediction models for blood-brain barrier permeation. , 2004, Current medicinal chemistry.

[34]  D. Begley,et al.  ABC transporters and the blood-brain barrier. , 2004, Current pharmaceutical design.

[35]  Vijay K Gombar,et al.  Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. , 2004, Journal of pharmaceutical sciences.

[36]  P. Barber,et al.  The rise and fall of NMDA antagonists for ischemic stroke. , 2004, Current molecular medicine.

[37]  R. Waterhouse,et al.  Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[38]  D. E. Clark.  In silico prediction of blood-brain barrier permeation. , 2003, Drug discovery today.

[39]  Emi Nakashima,et al.  New approaches to in vitro models of blood-brain barrier drug transport. , 2003, Drug discovery today.

[40]  Douglas B. Kitchen,et al.  Computational models to predict blood–brain barrier permeation and CNS activity , 2003, J. Comput. Aided Mol. Des..

[41]  D. Wong,et al.  Mechanism of new antipsychotic medications: occupancy is not just antagonism. , 2003, Archives of general psychiatry.

[42]  P. Whiting,et al.  The GABAA receptor gene family: new opportunities for drug development. , 2003, Current opinion in drug discovery & development.

[43]  H. Kubinyi.  Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[44]  J. Atack,et al.  Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. , 2003, Current drug targets. CNS and neurological disorders.

[45]  K. Lees,et al.  Excitatory amino acid antagonists for acute stroke. , 2003, The Cochrane database of systematic reviews.

[46]  A. Palmer.  Cholinergic therapies for Alzheimer's disease: progress and prospects. , 2003, Current opinion in investigational drugs.

[47]  D. Dormont,et al.  Atp Binding Cassette Multidrug Transporters Limit the Anti-HIV Activity of Zidovudine and Indinavir in Infected Human Macrophages , 2003, Antiviral therapy.

[48]  Jing Lin,et al.  The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. , 2003, Current topics in medicinal chemistry.

[49]  Stephen A. Wring,et al.  Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[50]  Meihua Rose Feng,et al.  Assessment of blood-brain barrier penetration: in silico, in vitro and in vivo. , 2002, Current drug metabolism.

[51]  Robert J Riley,et al.  The influence of DMPK as an integrated partner in modern drug discovery. , 2002, Current drug metabolism.

[52]  A. Palmer.  Pharmacotherapy for Alzheimer's disease: progress and prospects. , 2002, Trends in pharmacological sciences.

[53]  I. Muegge,et al.  "Holistic" in silico methods to estimate the systemic and CNS bioavailabilities of potential chemotherapeutic agents. , 2001, Current topics in medicinal chemistry.

[54]  R. J. Riley,et al.  Development of a Generalized, Quantitative Physicochemical Model of CYP3A4 Inhibition for Use in Early Drug Discovery , 2001, Pharmaceutical Research.

[55]  R. Sacco,et al.  Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. , 2001, JAMA.

[56]  A. Palmer,et al.  A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke , 2001, Brain Research.

[57]  Charles L. Wilson,et al.  Increased dopamine release in the human amygdala during performance of cognitive tasks , 2001, Nature Neuroscience.

[58]  D. Breimer,et al.  Methodological issues in microdialysis sampling for pharmacokinetic studies. , 2000, Advanced drug delivery reviews.

[59]  M. Hammarlund-Udenaes.  The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. , 2000, Advanced drug delivery reviews.

[60]  A. Beresford,et al.  ADME/PK as part of a rational approach to drug discovery. , 2000, Drug discovery today.

[61]  L. Schneider,et al.  Hydergine for dementia. , 2000, The Cochrane database of systematic reviews.

[62]  M. Alavijeh,et al.  Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine , 2000, British journal of pharmacology.

[63]  L P Longo,et al.  Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives. , 2000, American family physician.

[64]  O. Hornykiewicz,et al.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. , 1998, Klinische Wochenschrift.

[65]  P. Seeman,et al.  Therapeutic receptor-blocking concentrations of neuroleptics , 1995, Schizophrenia Research.

[66]  D. Calne,et al.  The Use of Pet in Parkinsons-Disease , 1995, Brain and Cognition.

[67]  P. Patsalos,et al.  The use of microdialysis for the study of drug kinetics: some methodological considerations illustrated with antipyrine in rat frontal cortex , 1995, British journal of pharmacology.

[68]  Y. Hurd,et al.  Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. , 1994, Clinical neuropharmacology.

[69]  S. Enna,et al.  Drugs and the brain , 1992, Nature.

[70]  M. Alavijeh,et al.  A freely moving and behaving rat model for the chronic and simultaneous study of drug pharmacokinetics (blood) and neuropharmacokinetics (cerebrospinal fluid): hematological and biochemical characterization and kinetic evaluation using carbamazepine. , 1992, Journal of pharmacological and toxicological methods.

[71]  R. Deane,et al.  Transport of Lead‐203 at the Blood‐Brain Barrier During Short Cerebrovascular Perfusion with Saline in the Rat , 1990, Journal of neurochemistry.

[72]  M. Albert,et al.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.

[73]  S. Walker,et al.  Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). , 1988, British journal of clinical pharmacology.

[74]  S. Rapoport,et al.  An in situ brain perfusion technique to study cerebrovascular transport in the rat. , 1984, The American journal of physiology.

[75]  R. Shanks,et al.  Comparison of the duration of effect of metoprolol and a sustained release formulation of metoprolol (betaloc-SA). , 1981, British journal of clinical pharmacology.

[76]  K D Pettigrew,et al.  Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. , 1978, The American journal of physiology.

[77]  W H Oldendorf,et al.  Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. , 1970, Brain research.

[78]  J. DiMasi.  The Value of Improving the Productivity of the Drug Development Process , 2012, PharmacoEconomics.

[79]  U. Bickel,et al.  How to measure drug transport across the blood-brain barrier , 2011, NeuroRX.

[80]  W. Löscher,et al.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family , 2011, NeuroRX.

[81]  Alan M Palmer,et al.  CNS drug discovery: challenges and solutions. , 2005, Drug news & perspectives.

[82]  Philip H. Elsinga,et al.  Positron Emission Tomography Studies on Binding of Central Nervous System Drugs and P-Glycoprotein Function in the Rodent Brain , 2005, Molecular Imaging and Biology.

[83]  J. Newcomer.  Second-Generation (Atypical) Antipsychotics and Metabolic Effects , 2005, CNS drugs.

[84]  Luca Cucullo,et al.  Drug delivery and in vitro models of the blood-brain barrier. , 2005, Current opinion in drug discovery & development.

[85]  W. Pardridge.  The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[86]  A. Palmer,et al.  Feature on Advances in Drug Discovery: Population Aging: A Challenge for CNS Drug Discovery , 2005 .

[87]  Mohammad S. Alavijeh,et al.  Feature on Advances in Drug Discovery 高齢化:中枢神経系医薬品創製へのチャレンジ , 2005 .

[88]  W. Löscher,et al.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[89]  H. van de Waterbeemd,et al.  Which in vitro screens guide the prediction of oral absorption and volume of distribution? , 2005, Basic & clinical pharmacology & toxicology.

[90]  P. Francis,et al.  Cholinesterase Inhibitors Used in the Treatment of Alzheimer’s Disease , 2004, Drugs & aging.

[91]  A. Sands,et al.  Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.

[92]  Andreas Reichel,et al.  An overview of in vitro techniques for blood-brain barrier studies. , 2003, Methods in molecular medicine.

[93]  S. Roberts.  Drug metabolism and pharmacokinetics in drug discovery. , 2003, Current opinion in drug discovery & development.

[94]  S W Allen,et al.  Recent advances in P450 research , 2001, The Pharmacogenomics Journal.

[95]  A. Avdeef,et al.  Physicochemical profiling (solubility, permeability and charge state). , 2001, Current topics in medicinal chemistry.

[96]  Michael Balls,et al.  Replacement Alternatives in Teaching. Progress in the reduction, refinement and replacement of Animal Experimentation , 1999 .

[97]  J R Chretien,et al.  Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. , 1998, Journal of drug targeting.

[98]  D. Calne,et al.  The use of PET in Parkinson's disease. , 1995, Brain and cognition.

[99]  M. Mark,et al.  Pharmacokinetics of continuous-release carbidopa/levodopa. , 1994, Clinical neuropharmacology.

[100]  E. Clarke,et al.  The human brain and spinal cord : a historical study illustrated by writings from antiquity to the twentieth century , 1968 .

[101]  E. Clarke.  The human brain and spinal cord , 1968 .